The U.S. Centers for Disease Control and Prevention (CDC) indicated that the JN.1 COVID-19 subvariant is increasingly across the United States, comprising potentially a third of all cases.
The variant comprised about 0.1 percent of all COVID-19 cases in the United States as of late October, according to the federal health agency in a Dec. 8 update. But as of Dec. 8, it now makes up about 15 to 29 percent of cases, it said.
Current COVID-19 treatments and tests are believed to be effective against JN.1, it said, adding that “the continued growth of JN.1 suggests that it is either more transmissible or better at evading our immune systems.”
The CDC also said it’s unclear to what extent JN.1 is contributing to hospitalizations in the U.S. but said that COVID-19 activity is likely going to increase during the winter months.
Researchers and the CDC say that JN.1 is a COVID-19 variant that descended from the BA.2.86 lineage, which is another Omicron sub-variant.
Symptoms
There is no data to indicate if JN.1 causes any new symptoms, said William Schaffner, a professor at the Vanderbilt University School of Medicine.“It’s an Omicron variant and looks to be similar,” he told the outlet.
The CDC says that symptoms include cough, shortness of breath, fever or chills, fatigue, muscle aches, loss of taste or smell, sore throat, runny nose, headache, vomiting, diarrhea, or nausea.
Other Respiratory Illnesses
At least 15 states are seeing “very high” or “high” levels of respiratory illness cases, the CDC said in a recent update.RSV, or respiratory syncytial virus, is a common cause of mild cold-like symptoms, but it can be dangerous for small children and older adults, health officials have said.
“The amount of respiratory illness (fever plus cough or sore throat) causing people to seek healthcare is elevated or increasing across most areas of the country. CDC is actively following up with health departments in these communities,” the agency said. “Emergency department visits due to influenza and COVID-19 are increasing, while visits due to RSV decreased slightly nationally.”

Earlier this month, the CDC said that despite reported spikes of pneumonia cases among children in several states, the CDC’s director, Mandy Cohen, said earlier this month that transmission rates are considered “typical.”
“As of today, we are not seeing anything that is atypical in terms of pneumonia-related emergency department visits,” she told reporters.
It came amid concerns that a spate of pediatric pneumonia cases in mainland China could spread to the U.S., which drew an alert from the ProMed global surveillance system in late November.